 | • レポートコード：C-MOR-100261 • 出版社/出版日：Mordor Intelligence / 2019年9月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、DNAシーケンシングの世界市場について調査・分析し、DNAシーケンシングの世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。 |
Market Overview
Global DNA Sequencing market is expected to witness a CAGR of 18.9% during the forecast period. Certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis & drug discovery, and growing investment in R&D.
The technological advancements in sequencing, from 2D sequencing in the 1970s to DNA sequencing, has come a long way. In recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of NGS technologies in 2005, they have had an incredible influence on genomic analysis. Next-generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. NGS technologies have been used for standard sequencing applications, like genome sequencing and for novel applications that were previously unexplored by using Sanger sequencing. Applications include whole-genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.
Scope of the Report
DNA sequencing is the procedure of determining or identifying the sequence of nucleotides within a DNA molecule. It enables scientists to sequence genes and genomes. After identifying and analyzing the genes from sequence information, scientists can get information about mutations which cause disease, thus providing vital medical information.
Key Market Trends
Next-Generation Sequencing is Expected to Show Lucrative Growth Opportunity in the Platform Segment
Next-Generation Sequencing can be of several types based on the technology. For example, the benefits offered by whole genome sequencing technique, such as ease of handling, affordability, and accuracy, are expected to boost their demand. Additionally, these tests are usually preferred by the market players as a single test, which is capable of providing information on multiple factors, such as virulence, serotype, and resistance. FDA is applying NGS in innovative ways, which can help reduce foodborne illnesses and deaths. Isolation of pathogens from food or environmental samples may be compared to clinical isolates from patients. A reliable link between the two is made, which helps define the scope of a foodborne illness outbreak. Owing to such factors the concerned segment is expected to observe steady growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America dominated the global market studied, in 2018, owing to the increased funding and support activities by the government and non-government entities, especially in the United States. By supporting genomics research, various government bodies, like NHGRI (National Human Genome Research Institute) have backed the work on sequencing of the human genome, and fund research on the genome’s structure, function, and role in health and disease. They also support studies on the ethical, legal, and social implications (ELSI) of genome research. The US National Human Genome Research Institute and the US National Academy of Medicine organized 90 leaders in genomic medicine from the United States, and 25 other countries in Genomic Medicine Symposium in 2014, to identify opportunities for collaborations that promote the responsible practice of genomic medicine.
Competitive Landscape
The DNA Sequencing market is highly competitive and consists of a few significant players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Inc., Merck KGaA, Pacific Biosciences of California, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., among others, hold the substantial market share in the DNA Sequencing market.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Technological Advancements in DNA Sequencing
4.2.2 Increasing Application in Clinical Diagnosis & Drug Discovery
4.2.3 Growing Investment in R&D
4.3 Market Restraints
4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
4.3.2 Legal and Ethical Issues
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 Instruments
5.1.2 Consumables (Kits, Reagents)
5.1.3 Others
5.2 Platform
5.2.1 Sanger
5.2.2 Next Generation Sequencing
5.2.3 Others
5.3 Application
5.3.1 Diagnostics
5.3.2 Personalized Medicine
5.3.3 Others (Biomarkers, Forensics, Reproductive Health, etc.)
5.4 End-User
5.4.1 Hospitals and Healthcare Organizations
5.4.2 Academics and Research Institutions
5.4.3 Pharmaceutical and Biotechnology Companies
5.4.4 Others
5.5 Geography
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 UK
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies, Inc.
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Danaher Corporation (Beckman Coulter, Inc.)
6.1.4 Eurofins Scientific
6.1.5 F. Hoffmann-La Roche
6.1.6 Illumina, Inc.
6.1.7 Merck KGaA
6.1.8 Pacific Biosciences of California, Inc.
6.1.9 PerkinElmer, Inc.
6.1.10 Thermo Fisher Scientific, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS